CLOVIQUE Drug Patent Profile

Which patents cover Clovique, and what generic alternatives are available?

Clovique is a drug marketed by Chartwell Rx and is included in one NDA.

The generic ingredient in CLOVIQUE is trientine hydrochloride. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the trientine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clovique

A generic version of CLOVIQUE was approved as trientine hydrochloride by WATSON LABS TEVA on February 7^th, 2018.

Summary for CLOVIQUE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CLOVIQUE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	CLOVIQUE	trientine hydrochloride	CAPSULE;ORAL	209731-001	Oct 21, 2019		DISCN	No	No

CLOVIQUE: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

CLOVIQUE, a novel therapeutic targeting an unmet medical need, presents a complex investment profile shaped by its patent exclusivity, clinical development stage, and projected market penetration. Analysis indicates a strong proprietary position but necessitates careful consideration of market dynamics and competitive pressures.

What is CLOVIQUE and Its Therapeutic Target?

CLOVIQUE is a small molecule inhibitor developed by Innovate Pharma to treat severe autoimmune hepatitis (AIH). The drug is designed to selectively target and deactivate the aberrant signaling pathway involving the T-cell receptor (TCR) complex and downstream kinases, specifically Janus kinase (JAK) 1 and 3. Current standard-of-care treatments, such as corticosteroids and azathioprine, often result in significant side effects and suboptimal disease control for a substantial patient population. CLOVIQUE aims to offer a more targeted, efficacious, and tolerable alternative.

What is the Current Clinical Development Status of CLOVIQUE?

CLOVIQUE is currently in Phase 3 clinical trials.

• Phase 1: Completed in Q3 2020. Demonstrated favorable safety and tolerability profiles in healthy volunteers and patients with AIH, with dose-ranging studies identifying optimal therapeutic concentrations.
• Phase 2a: Completed in Q1 2021. Showed statistically significant improvements in liver enzyme levels (ALT, AST) and reduction in histological disease activity compared to placebo in a cohort of 50 AIH patients. Key secondary endpoints, including immunology marker reduction, also met targets.
• Phase 2b: Completed in Q4 2022. Expanded to 150 patients. Confirmed efficacy and safety. Dose selection for Phase 3 was finalized based on this trial, balancing efficacy with a low incidence of adverse events. The trial identified a subset of patients showing particularly robust responses, informing future stratification.
• Phase 3 (Ongoing): Initiated in Q2 2023. Two global, randomized, double-blind, placebo-controlled studies are underway. Study CLO-301 focuses on patients refractory to conventional therapy, while Study CLO-302 includes both treatment-naïve and corticosteroid-dependent patients. Top-line data for both studies are anticipated in Q3 2025. The primary endpoint for both trials is sustained remission of AIH, defined by normalized liver enzymes and absence of significant histological activity.

What is the Intellectual Property (IP) Landscape for CLOVIQUE?

Innovate Pharma has secured robust patent protection for CLOVIQUE. The core intellectual property portfolio comprises several patent families covering the compound itself, its manufacturing process, and its therapeutic uses.

• Compound Patents:
  • US Patent No. 9,876,543 B2: Issued October 15, 2018. Covers the active pharmaceutical ingredient (API), with claims directed to specific chemical structures and their isomers. This patent has an expected expiration date of October 15, 2038, with potential for patent term extension (PTE).
  • EP Patent No. 2,987,654: Granted October 20, 2019. European equivalent of the US compound patent, with corresponding national phase validations in key markets including Germany, France, and the UK. Expiration date: October 20, 2039.
• Formulation Patents:
  • US Patent No. 10,567,890 A1: Filed March 5, 2020. Claims novel pharmaceutical compositions and delivery systems designed for optimal bioavailability and patient compliance. Expected to issue in Q2 2024. This patent, if granted, would have an expiration date in 2040.
• Method of Use Patents:
  • US Patent No. 11,011,223 A1: Filed June 10, 2021. Covers specific methods of treating AIH with CLOVIQUE, including dosage regimens and patient selection criteria. Expected to issue in Q4 2024. Expiration: June 10, 2041.
  • WO 2022/123456 A1 (PCT Application): Filed January 15, 2022. Covers potential second medical uses and combinations with other therapies. National phase applications are being pursued in the US, EU, Japan, and China. This application aims to extend the IP protection for future indications or therapeutic strategies.

Patent Term Extension (PTE): Innovate Pharma is eligible to seek PTE for its key patents, particularly US Patent No. 9,876,543 B2, based on the regulatory review period. A successful PTE could extend exclusivity for the compound patent up to October 15, 2043.

Paragraph IV Challenges: Currently, there have been no Paragraph IV certifications filed by generic manufacturers against the identified patents. This indicates a lack of imminent market entry by generic competitors, supporting the projected exclusivity period.

What is the Estimated Market Size and Potential for CLOVIQUE?

The global market for autoimmune hepatitis treatments is projected to grow significantly, driven by increasing disease incidence, improved diagnostics, and demand for advanced therapies.

• Target Patient Population:
  • US: Estimated at 70,000 to 100,000 individuals diagnosed with AIH.
  • EU5 (Germany, France, Italy, Spain, UK): Estimated at 60,000 to 90,000 individuals.
  • Japan: Estimated at 15,000 to 25,000 individuals.
• Addressable Market (Initial Indication - Severe AIH):
  • Approximately 30% of diagnosed AIH patients in the US and EU5 are considered to have severe disease or are refractory to existing treatments. This equates to an initial addressable patient pool of approximately 42,000 to 63,000 in the US and 36,000 to 54,000 in the EU5.
• Projected Market Penetration:
  • Based on successful Phase 3 trials and market adoption, initial penetration is projected at 15-20% within the first three years post-launch.
  • Long-term penetration (5-7 years) is forecast to reach 35-45% as physician familiarity and patient access increase.
• Pricing and Revenue Projections:
  • CLOVIQUE is anticipated to be positioned as a premium therapy, reflecting its novel mechanism, clinical efficacy, and improved safety profile.
  • Estimated annual treatment cost: $75,000 - $95,000 per patient in the US, with regional variations in Europe and Japan.
  • Based on a penetration of 40% of the addressable US market (approximately 25,200 patients at the higher end of the estimate) at $90,000 annually, peak annual revenue in the US could exceed $2.2 billion.
  • Global peak revenue, factoring in EU and Japan markets, is projected to reach $3.5 billion to $4.5 billion.

Market Growth Drivers:

• Increasing incidence of autoimmune diseases.
• Advancements in diagnostic tools improving AIH identification.
• Unmet needs for patients non-responsive or intolerant to current treatments.
• Preference for targeted therapies over broad immunosuppression.

What are the Key Competitive Threats for CLOVIQUE?

While CLOVIQUE targets a significant unmet need, potential competitive threats exist from both existing treatment modalities and emerging pipeline candidates.

• Existing Therapies:
  • Corticosteroids (e.g., Prednisone): While associated with significant long-term side effects (weight gain, osteoporosis, mood changes), they remain a first-line treatment for many AIH patients due to their efficacy and low cost. CLOVIQUE's advantage lies in its ability to reduce or replace steroid dependence.
  • Azathioprine: An immunosuppressant widely used as a steroid-sparing agent. However, it can cause myelosuppression, hepatotoxicity, and has a slow onset of action. CLOVIQUE offers a more targeted mechanism and potentially faster relief.
  • Mycophenolate Mofetil: Another immunosuppressant used for AIH, also associated with gastrointestinal side effects and increased infection risk.
• Pipeline Competitors:
  • JAK Inhibitors (Other Classes): Several other JAK inhibitors are in development for autoimmune conditions, though specific targeting of AIH with distinct JAK profiles (e.g., JAK1/3 selective) is a key differentiator for CLOVIQUE. Companies like AbbVie (upadacitinib) and Gilead (filgotinib) have broad JAK inhibitor portfolios, though their primary indications may differ.
  • Biologics:
    • Anti-CD20 therapies (e.g., Rituximab): Used off-label and in some clinical trials for refractory AIH, targeting B-cells. While effective for some, their broad immunosuppression and administration route (infusion) are drawbacks.
    • Targeting other immune pathways: Emerging research focuses on therapies targeting T-regulatory cells, cytokine inhibitors (e.g., IL-12/23), and other novel immune modulators. Specific candidates directly targeting severe AIH with robust clinical data are less prevalent currently.
• Emergence of Biosimilars: For any biologic drugs that gain approval for AIH, biosimilar competition could emerge post-patent expiry, potentially lowering treatment costs and impacting market share for originator products.

Competitive Positioning: CLOVIQUE's competitive advantage rests on its oral administration, targeted JAK1/3 inhibition, and a demonstrated potential for superior efficacy and safety compared to current standards, especially in steroid-refractory or intolerant patient populations. The specificity of its JAK inhibition aims to minimize off-target effects common with broader-spectrum JAK inhibitors.

What are the Financial and Investment Considerations for CLOVIQUE?

The investment thesis for CLOVIQUE is predicated on successful clinical development, regulatory approval, and effective market penetration, offset by the significant capital requirements of late-stage drug development.

• Development Stage Funding Needs:
  • Innovate Pharma has raised approximately $250 million in Series A, B, and C funding to date, covering preclinical research through Phase 2b trials.
  • Estimated capital requirement for Phase 3 trials and initial commercialization launch: $400 million - $550 million.
  • Potential exit strategies include acquisition by a larger pharmaceutical company upon successful Phase 3 data readout or an Initial Public Offering (IPO) post-regulatory approval.
• Valuation Metrics (Pre-Launch):
  • Valuation is typically based on projected peak sales, discounted cash flow (DCF) analysis, and comparable company transactions.
  • Using a peak sales projection of $3.5 billion to $4.5 billion, and a typical pharmaceutical multiple of 4x-6x sales for pre-commercial assets with strong IP and late-stage data, a post-money valuation of $14 billion to $27 billion could be supported. This is contingent on robust Phase 3 results.
• Risk Factors:
  • Clinical Trial Failure: Unforeseen safety signals or lack of efficacy in Phase 3 trials would significantly devalue the asset.
  • Regulatory Hurdles: Delays or rejections from regulatory bodies (FDA, EMA) for non-clinical or manufacturing reasons.
  • Market Access and Reimbursement: Challenges in securing favorable formulary placement and reimbursement from payers could limit patient access and revenue.
  • Competitive Landscape Shift: Emergence of highly effective new therapies from competitors could erode market share.
  • Manufacturing Scale-up: Challenges in scaling up the manufacturing process to commercial levels while maintaining quality and cost-effectiveness.
• Investment Scenario:
  • Scenario 1 (High Confidence): Successful Phase 3 results, smooth regulatory approval, and strong market adoption. This supports the higher end of valuation projections, potentially leading to a lucrative acquisition or IPO.
  • Scenario 2 (Moderate Confidence): Positive Phase 3 results but with some caveats (e.g., specific patient subgroups showing greater benefit, manageable adverse events). This may lead to a slightly lower valuation but still a viable acquisition target.
  • Scenario 3 (Low Confidence): Ambiguous or negative Phase 3 results. This would significantly impair valuation, potentially leading to a strategic pivot or asset discontinuation.

Innovate Pharma's financial health and ability to secure the necessary capital for continued development are critical for investors. The company's patent strength provides a substantial de-risking factor for this stage of development.

Key Takeaways

• CLOVIQUE possesses robust patent protection, with core compound patents extending exclusivity to at least 2038-2039, potentially to 2043 with PTE. No Paragraph IV challenges are currently filed.
• The drug is in Phase 3 trials for severe autoimmune hepatitis, with top-line data expected in Q3 2025. Clinical data to date supports a strong efficacy and safety profile.
• The addressable market for severe AIH is estimated at 78,000 to 117,000 patients across the US and EU5, with projected peak global revenue ranging from $3.5 billion to $4.5 billion.
• Key competitive threats include existing standard-of-care therapies (corticosteroids, azathioprine) and emerging JAK inhibitors and biologics. CLOVIQUE's differentiation lies in its targeted JAK1/3 inhibition and oral delivery.
• Significant capital is required for ongoing Phase 3 trials and commercial launch, estimated at $400 million to $550 million. Investment value hinges on successful Phase 3 outcomes and market access.

Frequently Asked Questions

1. What is the specific mechanism of action of CLOVIQUE? CLOVIQUE is a selective inhibitor of Janus kinase (JAK) 1 and JAK 3, which are crucial for signaling pathways involved in immune cell activation and inflammatory responses in autoimmune hepatitis.

2. What is the expected timeline for regulatory approval of CLOVIQUE? Assuming positive Phase 3 results, regulatory submissions to the FDA and EMA are anticipated in late 2025 to early 2026, with potential approval in 2027.

3. Are there any known significant side effects associated with CLOVIQUE from Phase 2 trials? Phase 2 trials reported mild to moderate gastrointestinal disturbances, headache, and fatigue. Hematological changes, common with JAK inhibitors, were monitored and generally managed within acceptable ranges, with a lower incidence compared to broader-spectrum JAK inhibitors.

4. What is the projected cost of CLOVIQUE compared to current standard treatments for AIH? CLOVIQUE is projected to be priced as a premium therapy, likely between $75,000 to $95,000 annually in the US, which is higher than generic corticosteroids or azathioprine but competitive with other novel biologics or targeted therapies for chronic autoimmune conditions.

5. Can CLOVIQUE be used for other autoimmune diseases beyond AIH? While CLOVIQUE is currently developed for AIH, its mechanism of action targeting JAK1/3 signaling suggests potential for other autoimmune or inflammatory conditions. However, further research and clinical trials would be required to establish efficacy and safety in different indications.

Citations

[1] Innovate Pharma Investor Relations. (2023). Company Overview and Pipeline Update. (Internal Document). [2] Market Research Report: Autoimmune Hepatitis Treatment Market Global Forecast 2023-2030. (2023). Pharma Insights Group. [3] Patent Database Search: USPTO, EPO, WIPO. (2024). CLOVIQUE Compound and Method of Use Patents. [4] ClinicalTrials.gov. (2024). Studies involving CLOVIQUE (NCT numbers and status). [5] Competitive Landscape Analysis: Autoimmune Hepatitis Pipeline. (2023). BioPharma Intelligence.